The authors investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe COVID-19 15 days or more after the second dose in adults.
We are extremely proud to announce that the EAN Congress has been named Best Corporate Event Subject to a Fee for the second consecutive year at the Evento Awards in Finland.
Latest Posts
-
-
Breaking newsCOVID-19
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
November 2, 2021In this article the authors used a matched test-negative, case–control study design to estimate vaccine effectiveness against any SARS-CoV-2 infection and against any severe, critical, or fatal case of COVID-19, from January 1 to September 5, 2021. -
Breaking newsCOVID-19
Waning Immune Humoral Response to BNT162b2 COVID-19 Vaccine over 6 Months
November 2, 2021In this article the authors conducted a 6-month longitudinal prospective study involving vaccinated health care workers who were tested monthly for the presence of anti-spike IgG and neutralizing antibodies. -
Paper of the MonthEAN NewsFeatured Slider
Research Paper of the Month: Association of Field Position and Career Length With Risk of Neurodegenerative Disease in Male Former Professional Soccer Players
November 1, 2021Our research paper of the month is a retrospective cohort study, aiming to investigate the association between field position, professional career length and playing era and increased risk of neurodegenerative disease among male former professional soccer players. -
Paper of the MonthCOVID-19Featured Slider
Covid-19 Paper of the month: Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study
November 1, 2021The aim of this study was to describe neurological and psychiatric complications of infection with SARS CoV 2 in children and adolescents and determine the prevalence of such manifestations in hospitalised patients under 18 years-old. -
Breaking newsCOVID-19
Characterizing long COVID in an international cohort: 7 months of symptoms and their impact
October 29, 2021This patient-led online research study enrolled 3762 participants with confirmed or suspected COVID-19, 93.2% of whom were experiencing symptoms after 28 days, referred as ‘Long COVID’. -
The Stroke Research Center Bern is conducting a survey on covert brain infarction, to gather information on current practice and attitudes towards covert brain infarctions from medical practitioners who encounter them in their daily work.
-
The European Brain Council will host an online event on the subject of 'Best practices for patient safety: An EU-wide view on the use of medicines off-label' on 30 November at 14:30 (CET).
-
News in general
Joint EADC/EAN Session on MCI: diagnosis, disclosure and management
October 27, 2021The European Academy of Neurology and the European Alzheimer's Disease Consortium hold a joint session on Wednesday, 1 December, 2021. -
Free EAN-BRAINS workshop taking place on 9-11 December.
-
Alzheimer Europe has published a new edition of its Dementia in Europe policy magazine, in an electronic format.
-
EAN has endorsed the ESRS's Sleep Medicine Texbook (2nd ed.) which is available to EAN members at the ESRS member price.
-
Read the latest reports on EAN clinical fellowships in London (UK) and Antwerp (BE)
-
Read the latest reports on EAN clinical fellowships in Unna (DE) and Graz (AT)!
-
InterviewsCOVID-19
COVID-19 around the World: Clinician interviews on experience and impact of the virus (Japan) – UPDATE
October 19, 2021Follow-up interview with Dr. Tsuyoshi Hamaguchi from the Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Japan.









